[go: up one dir, main page]

CA3152734A1 - Systeme et methode d'administration de multiples medicaments - Google Patents

Systeme et methode d'administration de multiples medicaments Download PDF

Info

Publication number
CA3152734A1
CA3152734A1 CA3152734A CA3152734A CA3152734A1 CA 3152734 A1 CA3152734 A1 CA 3152734A1 CA 3152734 A CA3152734 A CA 3152734A CA 3152734 A CA3152734 A CA 3152734A CA 3152734 A1 CA3152734 A1 CA 3152734A1
Authority
CA
Canada
Prior art keywords
tablet
capsule
drug
elagolix
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3152734A
Other languages
English (en)
Inventor
Yihong Qiu
Deliang Zhou
Mohamad SHEBLEY
Juki Wing-Keung NG
Ahmed Nader
Jian-Hwa HAN
David Metzger
Alexander RUGGLES
Hui ZU
Xi Shao
Yuchuan Gong
Yisheng Chen
Jian Gong
Min Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3152734A1 publication Critical patent/CA3152734A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un système d'administration de multiples médicaments qui comprend une première capsule comprenant un premier corps de capsule qui comprend un premier intérieur, et un premier comprimé et un deuxième comprimé à l'intérieur du premier intérieur. Le premier comprimé comprend un premier médicament, et le deuxième comprimé comprend au moins un second médicament différent du premier médicament. Le premier comprimé et le deuxième comprimé sont conçus pour une libération simultanée après dissolution du premier corps de capsule à l'intérieur d'un patient. Le système comprend également une seconde capsule comprenant un second corps de capsule qui comprend un second intérieur et un troisième comprimé à l'intérieur du second intérieur. Le troisième comprimé comprend le premier médicament.
CA3152734A 2019-08-29 2020-08-27 Systeme et methode d'administration de multiples medicaments Pending CA3152734A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962893567P 2019-08-29 2019-08-29
US201962893573P 2019-08-29 2019-08-29
US62/893,573 2019-08-29
US62/893,567 2019-08-29
US202062981180P 2020-02-25 2020-02-25
US62/981,180 2020-02-25
US202063022823P 2020-05-11 2020-05-11
US63/022,823 2020-05-11
PCT/US2020/048107 WO2021041608A1 (fr) 2019-08-29 2020-08-27 Système et méthode d'administration de multiples médicaments

Publications (1)

Publication Number Publication Date
CA3152734A1 true CA3152734A1 (fr) 2021-03-04

Family

ID=74683538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3152734A Pending CA3152734A1 (fr) 2019-08-29 2020-08-27 Systeme et methode d'administration de multiples medicaments

Country Status (9)

Country Link
EP (1) EP4021420A4 (fr)
JP (1) JP2022546496A (fr)
CN (1) CN114650810A (fr)
AU (1) AU2020336093A1 (fr)
BR (1) BR112022003895A2 (fr)
CA (1) CA3152734A1 (fr)
IL (1) IL290961A (fr)
MX (1) MX2022002526A (fr)
WO (1) WO2021041608A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040896A1 (fr) * 2020-08-25 2022-03-03 Abbvie Inc. Système et procédé d'administration de multiples médicaments
US11273128B1 (en) * 2021-04-15 2022-03-15 Sandoz Ag Elagolix formulation
JP7454692B2 (ja) * 2021-08-26 2024-03-22 寧徳時代新能源科技股▲分▼有限公司 液体カプセル、電池単体、電池および電力使用装置
CN113876728B (zh) * 2021-11-17 2022-12-13 南京唯创远医药科技有限公司 一种噁拉戈利冻干片及其制备方法
EP4279075B1 (fr) * 2022-05-12 2024-07-10 Zaklady Farmaceutyczne Polpharma S.A. Composition pharmaceutique contenant de l'elagolix

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
US20100255082A1 (en) * 2008-07-31 2010-10-07 Ishwar Chauhan Functionally Coated Breakable Tablets
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
EP3384930A1 (fr) * 2013-03-15 2018-10-10 AbbVie Inc. Procédés de traitement d'un saignement menstruel excessif
US9456987B2 (en) * 2013-04-03 2016-10-04 Binutra, Inc. Capsule with internal diaphragm
JP2019528132A (ja) * 2016-08-23 2019-10-10 ミラン インコーポレイテッド チャイルドレジスタント医薬品包装
WO2019036713A1 (fr) * 2017-08-18 2019-02-21 Abbvie Inc. Formulations pharmaceutiques solides pour le traitement de l'endométriose, de fibromes utérins, du syndrome des ovaires polykystiques et de l'adénomyose

Also Published As

Publication number Publication date
MX2022002526A (es) 2022-06-23
IL290961A (en) 2022-04-01
EP4021420A4 (fr) 2023-11-22
CN114650810A (zh) 2022-06-21
JP2022546496A (ja) 2022-11-04
AU2020336093A1 (en) 2022-03-31
WO2021041608A1 (fr) 2021-03-04
EP4021420A1 (fr) 2022-07-06
BR112022003895A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
CA3152734A1 (fr) Systeme et methode d'administration de multiples medicaments
US20210315900A1 (en) Solid dosage forms of palbociclib
JP4790597B2 (ja) 規定されたコア幾何学的配置を有する遅延放出錠
JP6259490B2 (ja) ベンダムスチンの経口投与形及びその治療的使用
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
US12083227B2 (en) Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
US20250000862A1 (en) Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
KR101667081B1 (ko) 이르베사르탄 및 암로디핀을 포함하는 고형의 고정 용량 제약 조성물, 그의 제법 및 그의 치료학적 용도
US20250213486A1 (en) Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
US20190054088A1 (en) Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
KR20090015890A (ko) 저 홍조 니아신 제형
Zhang et al. The development of minitablets for a pediatric dosage form for a combination therapy
EP3421033B1 (fr) Formulation d'atazanavir et de cobicistat pour le traitement du vih
WO2022040896A1 (fr) Système et procédé d'administration de multiples médicaments
US20250017932A1 (en) Methods of Administering Elagolix
Hodges et al. Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet
Pointe-Claire Pr ODAN ITRACONAZOLE
HK40002830A (en) Hiv treatment formulation of atazanavir and cobicistat
HK40002830B (en) Hiv treatment formulation of atazanavir and cobicistat